A Glimpse of ASH
Dr Isabel Cunningham discusses some of the important studies presented at the 2016 ASH meeting.
Diagnosis & Disease Information
DRd Superior to Rd Regardless of Time Since Last Therapy in Myeloma
Daratumumab plus lenalidomide and dexamethasone (DRd) is superior to lenalidomide plus dexamethasone (Rd).
DVd Superior to Vd Regardless of Prior Lines of Therapy in Myeloma
Daratumumab plus bortezomib and dexamethasone (DVd) is superior to bortezomib plus dexamethasone (Vd).
Idarubicin + HDAC ± Vorinostat Not Superior to 7+3 in AML
Idarubicin plus high-dose cytarabine (HDAC) with or without vorinostat was not superior to 7+3 chemotherapy.
Nilotinib Discontinuation Following Deep Molecular Response
Some patients with chronic myeloid leukemia (CML) who have maintained deep molecular responses for at least 2 years can safely discontinue nilotinib.
TKI Cessation Appears Feasible, Safe in Patients With CML
Tyrosine kinase inhibitor (TKI) cessation appears feasible and safe in patients with chronic myeloid leukemia in chronic phase (CML-CP).
No Impact of Detectable Disease on MRFS After Imatinib Cessation in CML
There were no differences in molecular relapse-free survival between patients with prior 4.5 log reduction but detectable disease and those with undetectable disease
CML-CP: Second TKI Discontinuation Safe and Successful
Tyrosine kinase inhibitors (TKIs) can be safely and successfully discontinued a second time despite failing first discontinuation.
ATRA + Arsenic Trioxide Active in Acute Promyelocytic Leukemia
All-trans retinoic acid (ATRA) plus arsenic trioxide with or without chemotherapy induces high remission rates.
Imatinib Generics Appear Non-inferior to Gleevec Brand Formulation in CML-CP
Generic formulations of imatinib appear to be non-inferior to Novartis’s Gleevec brand formulation with respect to clinical efficacy and tolerability.
- Loading...
Loading...
Next post in ASH 2016
Loading... 
Loading...